Thomas Sweet Buys Shares of Medline Inc. (MDLN)

On June 11, 2026, Thomas Sweet, an insider, acquired 5,387 shares of Medline Inc. (NasdaqGS: MDLN). This purchase was not part of a pre-planned trading program, and the shares were acquired at no cost.

Insider Buying and Selling at Medline Inc.

Thomas Sweet wasn't the only insider active on June 11. Todd Bluedorn and Richard Galanti also bought 5,387 shares each on the same day. This follows previous activity on December 16, 2025, when Sweet purchased 12,413 shares, Bluedorn acquired 10,345 shares, and Galanti bought 11,005 shares.

Other Institutional Activity in Medline Inc.

Several institutional investors have been adjusting their positions in Medline Inc. Carlyle Group Inc. reduced its holdings by 28.2 million shares, leaving it with 187.1 million shares valued at approximately $8.33 billion. Meanwhile, H&F Corporate Investors X, Ltd. decreased its stake by 13 million shares, ending with 86.5 million shares worth about $3.85 billion. On the other hand, FMR LLC increased its position by 10.2 million shares, bringing its total to 36.6 million shares valued at $1.63 billion. Capital Research Global Investors also added 8.4 million shares, resulting in a total of 23.2 million shares worth $1.03 billion. Invesco Ltd. made a significant move, increasing its holdings by 18.4 million shares to 20.9 million shares, valued at $932.9 million.

Medline Inc. Stock Up 3.8%

Shares of Medline Inc. are currently trading at $36.61 on the NasdaqGS. The company has a market capitalization of approximately $30.96 billion. Its price-to-earnings (P/E) ratio stands at 32.11, with a forward P/E of 21.94. Over the past 52 weeks, the stock has traded between $32.82 and $50.88. It has a 50-day moving average of $40.92 and a 200-day moving average of $42.67. The company's financial health is reflected in a current ratio of 4.41 and a quick ratio of 2.34, while its debt-to-equity ratio is 65.31.

Recent Earnings

Medline Inc. reported revenue of $29.14 billion, with a revenue growth of 10.7%. The company's net margin is 3.32%, and it has a return on equity (ROE) of 6.05%. The next earnings report is expected on August 5, 2026.

Analysts Set New Price Targets

On June 3, 2026, Baird maintained a 'buy' rating on Medline Inc. with a price target of $45. Similarly, Barclays also maintained a 'buy' rating with the same target on June 1. BNP Paribas kept a 'hold' rating with a $40 target on May 14. Tigress Financial, on May 13, set a $62 target while maintaining a 'buy' rating. The consensus among analysts is a 'buy' recommendation, with a mean target price of $51, based on 26 analyst opinions.

About Medline Inc.

Medline Inc., headquartered in Northfield, Illinois, is a leading provider of medical instruments and supplies. The company operates through two main segments: Medline Brand and Supply Chain Solutions. It offers a wide range of products, including surgical solutions, front line care products, and laboratory diagnostics. Medline serves various healthcare facilities such as hospitals, surgery centers, and nursing homes both in the United States and internationally. The company is led by CEO James M. Boyle and employs around 45,000 people.

Bottom Line

Thomas Sweet's recent purchase of Medline Inc. shares underscores ongoing insider interest in the company. Medline's stock is trading at $36.61, and it has shown solid financial performance with promising revenue growth. Institutional investors have been active, with some reducing and others increasing their stakes. Analysts generally maintain a positive outlook, with a consensus 'buy' rating and a target mean price of $51. As always, bear in mind that insider transactions and 13F filings are backward-looking and may not reflect current holdings.